IONS

75.25

0.27% -0.20

Vorhandelsmarkt: 75.22 -0.03 -0.04%

Ionis Pharmaceuticals Inc (IONS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$75.45

Offen:

$75.84

24-Stunden-Volumen:

850.25K

Relative Volume:

0.40

Marktkapitalisierung:

$12.44B

Einnahmen:

$1.06B

Nettoeinkommen (Verlust:

$-326.58M

KGV:

-35.80

EPS:

-2.1022

Netto-Cashflow:

$-977.73M

1W Leistung:

+4.83%

1M Leistung:

+0.62%

6M Leistung:

+0.76%

1J Leistung:

+123.66%

1-Tages-Spanne:

$74.82

$76.96

1-Wochen-Bereich:

$71.30

$77.76

52-Wochen-Spanne:

$31.66

$86.74

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Firmenname

Ionis Pharmaceuticals Inc

Sektor

Healthcare (1106)

Branche

Biotechnology (615)

Telefon

(760) 931-9200

Adresse

2855 GAZELLE COURT, CARLSBAD, CA

Mitarbeiter

1,402

Twitter

@ionispharma

Nächster Verdiensttermin

2026-04-29

Neueste SEC-Einreichungen

IONS's Discussions on Twitter

Compare IONS vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IONS Ionis Pharmaceuticals Inc	75.25	12.44B	1.06B	-326.58M	-977.73M	-2.1022
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-21	Eingeleitet	Canaccord Genuity	Buy
2026-04-10	Fortgesetzt	Raymond James	Outperform
2026-01-28	Fortgesetzt	Barclays	Overweight
2025-10-08	Hochstufung	JP Morgan	Neutral → Overweight
2025-09-26	Hochstufung	Goldman	Sell → Neutral
2025-09-03	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2025-07-31	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2025-07-01	Hochstufung	Barclays	Equal Weight → Overweight
2025-04-07	Eingeleitet	H.C. Wainwright	Buy
2025-03-31	Eingeleitet	Redburn Atlantic	Neutral
2024-08-02	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-07-24	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-07-16	Fortgesetzt	Jefferies	Buy
2024-06-14	Hochstufung	Bernstein	Underperform → Mkt Perform
2024-04-10	Hochstufung	Wolfe Research	Peer Perform → Outperform
2024-01-02	Hochstufung	BofA Securities	Neutral → Buy
2023-10-23	Hochstufung	BofA Securities	Underperform → Neutral
2023-09-29	Eingeleitet	Raymond James	Strong Buy
2023-07-31	Hochstufung	Citigroup	Neutral → Buy
2023-06-07	Fortgesetzt	Piper Sandler	Overweight
2023-05-04	Hochstufung	Citigroup	Sell → Neutral
2023-03-21	Eingeleitet	Bernstein	Underperform
2022-12-21	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-09-09	Fortgesetzt	Morgan Stanley	Overweight
2022-07-18	Fortgesetzt	Oppenheimer	Outperform
2022-03-31	Fortgesetzt	Piper Sandler	Overweight
2022-03-01	Eingeleitet	Citigroup	Sell
2022-03-01	Eingeleitet	Guggenheim	Buy
2022-02-01	Herabstufung	BofA Securities	Buy → Underperform
2021-12-14	Hochstufung	William Blair	Mkt Perform → Outperform
2021-05-07	Hochstufung	UBS	Sell → Neutral
2021-03-01	Hochstufung	Barclays	Underweight → Equal Weight
2020-12-16	Eingeleitet	UBS	Sell
2020-12-15	Hochstufung	Cowen	Market Perform → Outperform
2020-09-14	Fortgesetzt	JP Morgan	Neutral
2020-09-02	Eingeleitet	The Benchmark Company	Hold
2020-06-01	Fortgesetzt	Oppenheimer	Outperform
2020-05-13	Eingeleitet	RBC Capital Mkts	Outperform
2020-03-05	Eingeleitet	Citigroup	Buy
2019-12-13	Eingeleitet	Oppenheimer	Outperform
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-11-07	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2019-09-10	Hochstufung	Bernstein	Mkt Perform → Outperform
2018-08-08	Bestätigt	Stifel	Hold
2018-08-07	Bestätigt	Stifel	Hold
2018-05-08	Herabstufung	Evercore ISI	Outperform → In-line
2017-10-06	Fortgesetzt	Goldman	Sell
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-08-09	Bestätigt	Stifel	Hold
2017-03-10	Herabstufung	Goldman	Neutral → Sell
2016-12-28	Bestätigt	BMO Capital Markets	Outperform
2016-12-27	Bestätigt	Leerink Partners	Mkt Perform

Alle ansehen

Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten

May 04, 2026

MSN Money - MSN

May 04, 2026

Form 144: Option exercises listed; Joseph Loscalzo sold shares (IONS) - Stock Titan

May 04, 2026

Ionis well-positioned for continued momentum and substantial valu - The National Law Review

May 04, 2026

Ionis Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript - GuruFocus

May 03, 2026

Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

May 03, 2026

Kornitzer Capital Management Inc. KS Buys Shares of 29,105 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

May 03, 2026

May 02, 2026

Discipline and Rules-Based Execution in IONS Response - Stock Traders Daily

May 02, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) Stock Rating Upgraded by Wall Street Zen - MarketBeat

May 02, 2026

May 01, 2026

VY(R) T. Rowe Price Diversified Mid Cap Growth Portfolio's Ionis Pharmaceuticals Inc(IONS) Holding History - GuruFocus

May 01, 2026

Analysts’ Top Healthcare Picks: Ionis Pharmaceuticals (IONS), Teladoc (TDOC) - The Globe and Mail

May 01, 2026

Ionis Pharmaceuticals | SCHEDULE 13G: Others - Moomoo

May 01, 2026

Ionis to present at upcoming investor conferences - The National Law Review

May 01, 2026

Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st

May 01, 2026

Research Alert: CFRA Raises Rating On Shares Of Ionis Pharmaceuticals, Inc. To Buy From Hold - Moomoo

May 01, 2026

Vanguard Group Inc. Sells 41,271 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

May 01, 2026

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Ionis Pharmaceuticals (IONS) and GE Healthcare Technologies Inc (GEHC) - The Globe and Mail

May 01, 2026

IONS Maintained by Barclays -- Price Target Raised to $115 - GuruFocus

May 01, 2026

Atle Fund Management AB's Ionis Pharmaceuticals Inc(IONS) Holding History - GuruFocus

May 01, 2026

Ionis Pharmaceuticals Projects Ozarsen Sales Exceeding 3 Billion Dollars - HarianBasis.co

May 01, 2026

Apr 30, 2026

Ionis (NASDAQ: IONS) EVP sells 1,626 shares under Rule 10b5-1 plan - Stock Titan

Apr 30, 2026

Hereditary Angioedema Market: Rapid Increment Driven by Innovation by 2034DelveInsight - openPR.com

Apr 30, 2026

Narrow-Moat Ionis' Peak Sales Raised for Olezarsen; Positive Outlook as Late-Stage Assets Advance - Morningstar

Apr 30, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat

Apr 30, 2026

IONS Maintained by RBC Capital -- Price Target Raised to $100 - GuruFocus

Apr 30, 2026

Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.

Apr 30, 2026

Oppenheimer Adjusts Price Target on Ionis Pharmaceuticals to $110 From $104, Maintains Outperform Rating - marketscreener.com

Apr 30, 2026

Vanguard reports 5.05% stake in Ionis Pharmaceuticals (NASDAQ: IONS) - Stock Titan

Apr 30, 2026

IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View - TradingView

Apr 30, 2026

Stifel Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Raises Target Price to $86 - Moomoo

Apr 30, 2026

A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $100 to $125 - Moomoo

Apr 30, 2026

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2026 Earnings Call Transcript - Insider Monkey

Apr 30, 2026

Ionis Pharmaceuticals Q1 2026 earnings preview - MSN

Apr 30, 2026

IONS Maintains Buy Rating by HC Wainwright & Co. -- Price Target Raised to $125 - GuruFocus

Apr 30, 2026